Factors Likely to Have Influenced Earnings Results NASDAQ:CERE, NASDAQ:ACET, NASDAQ:VERO, NASDAQ:UNAM

CEREVEL THERAPEUTICS (NASDAQ:CERE) EARNINGS INFORMATION (NASDAQ:CERE)

Cerevel Therapeutics last posted its quarterly earnings results on May 16th, 2021. The biotechnology company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.01. Cerevel Therapeutics has generated $0.00 earnings per share over the last year.

IS CEREVEL THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:CERE)

4 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Cerevel Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Cerevel Therapeutics stock.
Cerevel Therapeutics

ADICET BIO (NASDAQ:ACET) EARNINGS INFORMATION (NASDAQ:ACET)

Adicet Bio last posted its quarterly earnings data on May 16th, 2021. The reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.34. Adicet Bio has generated ($16.86) earnings per share over the last year. Adicet Bio has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, July 29th, 2021 based off prior year’s report dates.

IS ADICET BIO A BUY RIGHT NOW? (NASDAQ:ACET)

9 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Adicet Bio in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Adicet Bio stock.
Adicet Bio

VENUS CONCEPT (NASDAQ:VERO) EARNINGS INFORMATION (NASDAQ:VERO)

Venus Concept last announced its quarterly earnings data on March 29th, 2021. The reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.06. The firm had revenue of $25.83 million for the quarter, compared to the consensus estimate of $25.70 million. Venus Concept has generated ($4.77) earnings per share over the last year. Venus Concept has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, August 12th, 2021 based off prior year’s report dates.

IS VENUS CONCEPT A BUY RIGHT NOW? (NASDAQ:VERO)

5 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Venus Concept in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Venus Concept stock.
Venus Concept

UNICO AMERICAN (NASDAQ:UNAM) EARNINGS INFORMATION (NASDAQ:UNAM)

Unico American last posted its earnings data on March 1st, 2021. The insurance provider reported ($0.39) earnings per share for the quarter. The business had revenue of $8.32 million for the quarter. Unico American has generated $0.00 earnings per share over the last year. Unico American has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, August 13th, 2021 based off prior year’s report dates.

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN UNICO AMERICAN? (NASDAQ:UNAM)

Wall Street analysts have given Unico American a “N/A” rating, but there may be better buying opportunities in the stock market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Unico American wasn’t one of them. MarketBeat thinks these five companies may be even better buys.